Molbio Diagnostics Eyes ₹940 Crore Through IPO for Expansion

Molbio Diagnostics, a key player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise ₹940 crore. The company will generate ₹200 crore through fresh issuance of shares to bolster its capital expenditures. An additional ₹740 crore is expected from an offer for sale, which will see the promoter group's stake reduced from 46.6% to 43%.

Strategic Global Expansion

With six manufacturing sites across India, Molbio serves over 90 countries worldwide. The company's growth has been largely driven by its tuberculosis diagnostic test kits, which account for a significant portion of its revenue. The firm has also developed the 'Truenat' platform, a portable diagnostic system designed for resource-limited settings, capable of delivering accurate test results within an hour. The platform supports over 30 diseases through 43 diagnostic assays.

Government and international aid agencies make up more than 80% of Molbio's revenue, highlighting the company's reliance on these sectors. The firm's top clients contribute over half of its revenue, indicating a concentration risk that potential investors must consider.

Financial Performance and Market Position

Between FY24 and FY26, Molbio's revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore. Net profit grew by 40.2% annually to ₹164.1 crore during the same period. The company's EBITDA rose 33.2% to ₹328.2 crore, with an EBITDA margin improving from 22% in FY24 to 22.6% in FY26. In FY26 alone, revenue saw a 41.7% year-on-year increase, while EBITDA and net profit grew by 27.9% and 18.4%, respectively.

The IPO values Molbio at a price-earnings (P/E) multiple of up to 57, which is comparable to other Indian healthcare diagnostics and medical device companies. These include Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81.

High-Risk Investment Potential

Molbio Diagnostics' IPO presents a potential opportunity for high-risk investors seeking long-term growth. The company's robust financial performance and strategic global presence underscore its potential for continued expansion. However, the reliance on a concentrated customer base and significant dependency on government and international aid agencies pose inherent risks.

Incorporated in 2000, Molbio has established itself in the research, development, and manufacturing of diagnostic solutions for both infectious and non-communicable diseases. Besides its primary focus on molecular diagnostics, the company, through its subsidiaries and strategic collaborations, offers radiology, digital pathology, and breast health screening solutions.